PsyBio Therapeutics Inc. is developing biosynthetic psychoactive compounds that offer a new treatment paradigm to reverse the course of mental health issues.
In partnership with Miami University, the company is leveraging a proprietary platform technology to biologically synthesize psilocybin and other targeted next generation active compounds in Psilocybe Cubensis and other fungi and plants.
The company's platform has the potential to offer a 32X improvement in psilocybin yields, which currently cost an estimated $2,000 per gram of pharmaceutical grade product. Meanwhile, the company's clinical programs are focused on the treatment of cancer-related depression with four candidates in its pipeline.
Co-Founder, CEO & Director
Co-Founder, CFO & Director
Co-Founder & Advisor
Dr. J. Andrew Jones
Chairman, Scientific Advisory Board